Global Mesna (Mesnex) Market Size By Product Type (Oral, Injections), By Application (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast

Mesna (Mesnex) Market Size And Forecast

Mesna (Mesnex) Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Increasing cancer incidence coupled with rising practices of chemotherapy has increased demand for Mesna. The chemotherapy is going through a phase of evolution and rapid progress leads to growth of the market during the forecast period. The Global Mesna (Mesnex) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Mesna (Mesnex) Market Definition

Mesna, also known as Mesnex, is a medicine that is intended to reduce the risk of bladder hemorrhage in people who are taking cyclophosphamide or ifosfamide. It can be taken orally or injected into a vein. Headache, vomiting, tiredness, loss of appetite, cough, rash, and joint discomfort are all common adverse effects. Allergic responses are a serious negative effect. Although use during pregnancy appears to be safe for the infant, it has not been well researched. Mesna is a sulfur-containing organ sulfur chemical. It acts by making the cyclophosphamide and ifosfamide breakdown products present in the urine less harmful. In 1988, Mesna received FDA approval for medical use in the United States. It is listed as an essential medicine by the World Health Organization.

When a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy, Mesna is used to lower the risk of hemorrhagic cystitis and haematuria. In vivo, these two anticancer drugs can be transformed into urotoxic metabolites like acrolein. Mesna’s sulfhydryl group reacts with, unsaturated carbonyl-containing molecules like acrolein to help detoxify these metabolites. A Michael addition is the name for this reaction. Mesna also improves cysteine excretion in the urine. It can be given intravenously or orally (through the mouth). Oral Mesna would be administered with oral cyclophosphamide, and IV Mesna would be given with IV ifosfamide.

Due to bioavailability difficulties, oral Mesna doses must be doubled compared to IV Mesna doses. Instead of staying four to five days in the hospital for all of the IV Mesna infusions, patients can leave sooner with the oral preparation. Mesna lowers the toxicity of urotoxic chemicals that may arise as a result of chemotherapy. Mesna is a water-soluble antioxidant chemical that is given in combination with the chemotherapy drugs cyclophosphamide and ifosfamide. Mesna concentrates in the bladder, where acrolein accumulates after chemotherapy and forms a conjugate with acrolein and other urotoxic metabolites via a Michael addition. The urotoxic chemicals are converted to innocuous metabolites by this conjugation event. After then, the metabolites are eliminated in the urine.

Global Mesna (Mesnex) Market Overview

Mesna is taken as a pill or injected into the veins at two and six hours after each ifosfamide dose as a prophylactic medication to lower the risk of ifosfamide-induced hemorrhagic cystitis when used in conjunction with normal antineoplastic therapy. The daily dose of Mesna is hundreds of times higher than that of ifosfamide. Mesnex (Mesna) tablets are a type of tablet. The need for Mesna has increased as the incidence of cancer has increased, as has the use of chemotherapy. Chemotherapy is in the process of evolving and progressing rapidly. Cancer cases were anticipated to reach 1,735,350 in 2018, and this number is expected to rise by 3% each year.

Clinical research for new treatments like hemorrhagic cystitis is boosting the market’s growth and increasing FDA approvals for new therapeutics, which is allowing Mesna to expand its reach. Ifosfamide and cyclophosphamide, two chemotherapy medications, can irritate the bladder lining. This can induce bladder bleeding, which can show up as blood in your urine (pee). This is referred to as haematuria. Mesna protects your bladder against irritation and bleeding by acting as a barrier.

Ifosfamide is always given with Mesna. The majority of persons who receive cyclophosphamide treatment do not receive dosages high enough to cause bladder hemorrhage. They will not require the use of Mesna. However, if your treatment includes high doses of cyclophosphamide, you will be given Mesna. If you’re taking a high dose of cyclophosphamide, your doctor can tell you. Outside of North America, Mesna is also utilized as a mucolytic agent, similar to acetylcysteine it’s marked as Mistabron and Mistabronco for this purpose.

Global Mesna (Mesnex) MarketSegmentation Analysis

The Global Mesna (Mesnex) Market is Segmented on the basis of Product Type, Application, and Geography.

Mesna (Mesnex) Market, By Product Type

• Oral
• Injections

Based on Product Type, The market is segmented into Oral and Injections. The Oral Segment was dominated Global Mesna (Mesnex) Market during the forecast period. Due to bioavailability difficulties, oral Mesna doses must be doubled compared to IV Mesna doses. Instead of staying four to five days in the hospital for all of the IV Mesna infusions, patients can leave sooner with the oral preparation.

Mesna (Mesnex) Market, By Application

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Application, The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. During the forecast period, Retail Pharmacies held the largest share of the market. Future pharmacies will be high-tech shopping malls with services like telemedicine and point-of-care diagnostics. The major players have already begun to incorporate more technology into their operations.

Mesna (Mesnex) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Geography, The Global Mesna (Mesnex) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In the future years, North America is expected to reach the largest share during the forecast period. Chemotherapy is undergoing numerous R&D phases as a result of expansion, which includes an increase in cancer occurrences combined with the expanding use of chemotherapy. Clinical trials are still being conducted for new treatments, and the FDA is approving more new drugs.

Key Players

The “Global Mesna (Mesnex) Market” study report will provide a valuable insight with an emphasis on the global market including some of the major player’s such as Sagent Pharmaceuticals, Athenex Pharmaceuticals, Fresenius Kabi, Baxter, Mylan, Teva Pharmaceutical, Gland Pharma Limited, Hikma Pharmaceuticals, and Jiangsu Hengrui Medicine.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In July 2019, Mylan and Upjohn, a division of Pfizer, will merge, forming a new global health champion that is uniquely positioned to meet the world’s medical needs.

• In January 2022, Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical business, has entered into a license agreement with Medication Patent Pool (MPP) in the Middle East and North Africa (MENA) region for molnupiravir, MSD’s investigational oral COVID-19 antiviral medicine.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.